Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Blueprint Medicines (BPMC) Reports Q4 Net Loss of $5.40
February 16, 2022 7:05 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($5.40), $3.75 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $107.02 million versus the consensus estimate of $102.69 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More